Immunogenicity of Protein Therapeutics: Therapeutic proteins are susceptible to aggregation in response to a wide variety of stresses encountered during their manufacture, storage and delivery to ...

fusion proteins and multi-specifics. These are likely to dominate the future antibody therapeutic market, but many of them express poorly and have aggregation issues leading to delays to projects.